Hahn Loeser’s Hervé Jacquiau Passes Bar Exam; Adds Depth to Chicago Office

Hervé Jacquiau, J.D., Ph.D., M.Sc., D.E.A.

Hahn Loeser & Parks LLP is pleased to announce that Dr. Hervé Jacquiau passed the Illinois state bar exam and is now an attorney in the firm’s Chicago office, where he will focus his legal practice in the areas of Intellectual Property, Business Development and Research & Development.

“Hervé’s impressive background has been a tremendous asset to our IP clients over the years as he served as a patent agent and technical advisor,” states Steven E. Feldman, Chair of the firm’s Intellectual Property Practice Group and Partner-in-Charge of its Chicago Office. “Hervé’s experience is an asset to our national IP practice.”

Formerly a patent agent and technical advisor with the firm, Hervé has years of experience managing patent prosecution and litigation. His background covers a variety of technologies, particularly biotechnology (e.g. biofuels, fermentation processes); chemical engineering, molecular pharmacology and biochemistry (e.g. pharmaceuticals, biosimilars); cell biology, genetics and microbiology (e.g. biosensors, medical research, oncology); food and biology industries (e.g. wine, antibiotics and antibody production).

Hervé received his Ph.D. from the University of Cambridge after investigating the genetic and biochemical features responsible for the biodegradation of toxic pollutants. He developed novel genetic tools to develop biosensors and became co-inventor (U.S. Patent No. 6,849,442). His work contributed to the creation of a biotechnology company that specializes in developing biosensors for the detection and removal of environmental contaminants.

As a postdoctoral research associate at St. Jude Children’s Research Hospital, Hervé investigated various mechanisms that regulate cellular sensitivity or resistance to anti-cancer agents. He investigated DNA rearrangements and cell-cycle regulation and highlighted the role of various mechanisms of protein degradation in modulating cellular response to enzyme inhibitors that are commonly used in the treatment of childhood cancer.

Hervé previously worked at the Lankenau Institute for Medical Research (LIMR), where he conducted translational research and developed antibodies to be used in cancer diagnostics or research tools. At the institute, Hervé evaluated scientific innovations and business proposals to develop IP strategies and to expand LIMR’s biotechnology incubators. He subsequently became a business and scientific funding associate in the Department of Business Development.

Hervé contributed to the creation of a novel drug screening facility for drug target validation and drug discovery, as well as a center for the production of human antibodies to be used as medical diagnostics or as novel therapeutics. He collaborated with surgeons and clinicians to develop protocols for clinical trials. Hervé also wrote proposals to attract funding and to promote scientific collaborations.

Earlier in his career, Hervé earned master of science degrees in bioreactor systems and biotechnology. As an undergraduate, he studied biological sciences, as well as food and biological industries.